M&A in India jumpstarts top-line growth

18 July 2022

India’s healthcare and pharmaceutical sector recorded hectic deal activity with the value of merger and acquisitions (M&A) in the first six months of 2022 scaling a record high to touch $4.32 billion compared to $2.02 billion in the comparative period last year, and crossing the total deal value of $3.35 billion in 2021.

Setting a record M&A deal value in the sector was Biocon (BSE: 532523) subsidiary Biocon Biologics' definitive agreement this February to buy Viatris’ (Nasdaq: VTRS) global biosimilar portfolio for $3.34 billion. The deal received approval from the Competition Commission of India last month.

Another big-ticket deal occurred during the period as Mankind Pharma agreed to pay $249 million for Panacea Biotec's formulation business in India and Nepal.

With the healthcare and pharmaceutical industry in India headed towards aggregation, consolidation and bigger deal sizes, analysts say more foreign companies will be interested in strategic transactions in the future, though valuations will continue to pose a challenge.

Private equity deals

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK